Concizumab, Elranatamab & Talquetamab Among New EU Filings At EMA
Executive Summary
The European Medicines Agency has started reviewing a new batch of medicines for potential pan-EU marketing approval.
You may also be interested in...
New EU Filings
Zolbetuximab, Astellas’ Claudin 18.2-targeting cancer drug, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
New EU Filings
Fruquintinib, Takeda/Hutchmed’s treatment for adult patients with previously treated metastatic colorectal cancer, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.
New EU Filings
Danicopan, from AstraZeneca, for the treatment of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.